Novartis Negotiates its Way into the US Migraine Market
Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring…
Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring…
UPDATE (19/04/2017): CTL019 has been granted Breakthrough Designation by the FDA for relapsed/refractory diffuse large…
Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining…
After exploring Munich and the Golden Triangle, we head to another biotech hotspot full of people…
Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances…
PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping…
Try as we might, we can’t cover all the biotech news out there! Here’s a roundup…
Developments in cancer treatments accelerating, and the market is expanding. Where does Europe stand? Cancer…
A new report listing the top drug launches this year reveals the strong performance of…
Novartis has announced excellent results for 2016. Could its strong focus on biotech be the…
Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that…
Try as we might, we can’t cover all the biotech news out there, especially with…